Sepúlveda-Hermosilla, GonzaloFreire, MatíasBlanco, AlejandroCáceres, JavierLizana, RodrigoRamos, LilianaAssar, RodrigoAmpuero, DiegoAren, OsvaldoChernilo, SaraSpencer, María LoretoBernal, GiulianoFlores, JacquelineRasse, GermánSánchez, CarolinaMarcelain, KatherineRivas, SolangePereira Branco, GabrielaGalli de Amorim, MaríaNoronha Nunes, DianaDias-Neto, EmmanuelFreitas, Helano C.Fernández, CristinaPérez, PaolaNIRVANA teamArmisén, Ricardo2021-08-032021-08-032021-06The Journal of Molecular Diagnostics, 2021 jun, 36 p.https://doi.org/10.1016/j.jmoldx.2021.05.018http://hdl.handle.net/11447/4215About 4 to 7 % of the Non-small cell lung cancer patients have ALK rearrangements and specific target therapies improve patients’ outcomes significantly. ALK gene fusions are detected by immunohistochemistry (IHC) or Fluorescent in situ Hybridization (FISH) as gold standards in South America. Next Generation Sequencing (NGS) based assays are a reliable alternative, able to perform simultaneous detection of multiple events from a single sample. We analyzed 4,240 Non-small cell lung cancer samples collected in 37 hospitals from Chile, Brazil, and Peru; where ALK rearrangements were determined as part of their standard of care (SofC) using either IHC or FISH. A subset of 1450 samples was sequenced with the Oncomine Focus Assay (OFA), and the concordance with the SofC tests was measured. An orthogonal analysis was performed using a qPCR EML4-ALK fusion detection kit. ALK fusion prevalence is very similar for Chile (3.67%, N=2142), Brazil (4.05%, N=1013) and Peru (4.59%, N=675). Whereas a comparison between OFA and SofC assays showed similar sensitivity, OFA had significantly higher specificity and higher positive predictive value, which opens new opportunities for a more specific determination of ALK gene rearrangements.36 p.enLung cancerALKArticle